The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates

Drug Updates

March 1, 2009 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Safety Issues: Interactions, Label Changes, and Warnings

Anti-Epileptic Drugs (AEDs): In 2008, the Food and Drug Administration (FDA) informed healthcare professionals that they were analyzing reports of suicidality (suicidal behavior or ideation) from placebo-controlled trials of 11 AEDs.1 These agents are used to treat psychiatric disorders, pain, epilepsy, and other conditions. In the FDA analysis, they found that patients treated with AEDs had about twice the risk of suicidal behavior or ideation (0.43%) compared with patients receiving placebo (0.22%). This was noted as soon as one week after starting therapy until 24 weeks of therapy. The results were relatively consistent among all agents. The relative risk for suicidality was higher in epilepsy patients compared with patients using an AED for another condition.2

You Might Also Like
  • Drug Updates
  • Drug Updates
  • Drug Updates
Explore This Issue
March 2009
Also By This Author
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Based on these outcomes (completed in December 2008), the FDA mandated that all manufacturers of AEDs include a label warning and develop a medication guide for patients dispensed these agents, informing them of these risks. The complete list of AEDs includes:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR);
  • clonazepam (Klonopin);
  • clorazepate (Tranxene);
  • divalproex sodium (Depakote, Depakote ER, Depakene);
  • ethosuximide (Zarontin);
  • ethotoin (Peganone);
  • felbamate (Felbatol);
  • gabapentin (Neurontin);
  • lamotrigine (Lamictal);
  • lacosamide (Vimpat);
  • levetiracetam (Keppra, Keppra XR);
  • mephenytoin (Mesantoin);
  • methsuximide (Celontin);
  • oxcarbazepine (Trileptal);
  • phenytoin (Dilantin Suspension);
  • pregabalin (Lyrica);
  • primidone (Mysoline);
  • rufinamide (Banzel);
  • tiagabine (Gabitril);
  • topiramate (Topamax);
  • trimethadione (Tridione);
  • and zonisamide (Zonegran).3

Bisphosphonates (BPs) and Osteonecrosis of the Jaw (ONJ): Sedghizadeh et al. reported on their single-institution, retrospective evaluation of the electronic medical records at the University of Southern California (USC) in Los Angeles for patients that were diagnosed with ONJ and had received or were receiving alendronate.4 Their intent was to determine if ONJ occurrence is more common than had been suggested by the FDA or the American Dental Association’s (ADA’s) expert panel. Initially reported as a rare occurrence at an incidence of 0.7 per 100,000 person-years of exposure or 170 cases worldwide, these investigators identified 208 patients with a history of alendronate use. Of these 208 patients, nine had active ONJ and were being treated in the USC dental clinic. These nine patients corresponded to one in 23 patients receiving alendronate, or about 4% of the population. All cases occurred after tooth extraction or denture trauma resulting in jawbone exposure. BPs are thought to inhibit osteoclast function, leading to cell death and an overall decrease in bone breakdown. Once BPs are integrated into mineralized bone, they stay in the bone for a long time; due to their long half-lives, ONJ can occur long after patients have discontinued BP treatment as well as while they are on therapy. Most ONJ cases have occurred in the newer generation nitrogen-containing BPs which include alendronate, ibandronate, pamidronate, risedronate, and zoledronate.5 The ADA Scientific Affairs Council states that routine dental treatment should not be changed based on BP use.6

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates Tagged With: Approvals, PipelineIssue: March 2009

You Might Also Like:
  • Drug Updates
  • Drug Updates
  • Drug Updates
  • Drug Updates

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.